Erik Meredith

This inventor holds 18 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Novartis Ag. Active years: 2012-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erik Meredith. Retrieved from https://idiyas.com/inventor/erik-meredith

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 5)

% Patents Active = 77.8

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 9.1

ph-index = 3

Forward Citations = 55(Granted Patents)

Location History:

Cambridge, MA (US) (2012 - 2013)
Hudson, MA (US) (2012 - 2020)

Company Filing History:

18 out of 3,978

Novartis Ag

patents

Years Active: 2012-2024

Loading Chart...

Areas of Expertise:

Hydroquinazoline Derivatives

Indane Derivatives

Indoline Derivatives

Guanylate Cyclase Activators

C5A Receptor Modulators

Adrenal Hormone Agents

Heterobicyclic Carboxamides

Kinase Inhibitors

Organic Compounds

Tetrahydropyrido-Pyridine

Tetrahydropyrido-Pyrimidine

Cyclohexen-1-yl-Pyrazole

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12129246 - Hydroquinazoline derivatives for the treatment of a disease or disorder (2024-10-29),

2. 10550102 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2020-02-04),

3. 10208018 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2019-02-19),

4. 9957254 - Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2018-05-01),

5. 9765067 - Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2017-09-19),

6. 9505755 - Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5A receptor modulators (2016-11-29),

7. 9434754 - Use of an adrenal hormone-modifying agent (2016-09-06),

8. 9278969 - Organic compounds (2016-03-08),

9. 8846656 - Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators (2014-09-30),

10. 8835646 - Organic compounds (2014-09-16),

11. 8609862 - Use of an adrenal hormone-modifying agent (2013-12-17),

12. 8541432 - Heterobicyclic carboxamides as inhibitors for kinases (2013-09-24),

13. 8501756 - Heterobicyclic carboxamides as inhibitors for kinases (2013-08-06),

14. 8492393 - Heterobicyclic carboxamides as inhibitors for kinases (2013-07-23),

15. 8486954 - Heterobicyclic carboxamides as inhibitors for kinases (2013-07-16),

Title: The Innovative Mind of Erik Meredith

Introduction

Erik Meredith, an esteemed inventor based in Hudson, MA, has made significant contributions to the field of pharmaceuticals and medicinal chemistry. With an impressive portfolio of 18 patents, he stands out as a prominent figure in innovation, particularly within Novartis AG, a leading global healthcare company dedicated to the development of advanced medicines.

Latest Patents

Erik's latest patents showcase his creativity and commitment to improving health outcomes. One such patent involves Hydroquinazoline derivatives for the treatment of diseases or disorders. This disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which encompasses specific substitutions as described in the documentation. This innovation includes compositions and methods for utilizing these compounds effectively.

Another notable patent from Erik involves indane and indoline derivatives that act as soluble guanylate cyclase activators. This patent presents a compound of formula (I), alongside a method for manufacturing these compounds and detailing their therapeutic uses. Furthermore, it offers combinations of pharmacologically active agents and pharmaceutical compositions aimed at enhancing patient care.

Career Highlights

Throughout his career, Erik has continuously pushed the boundaries of innovation in pharmacology. His extensive research and development efforts have not only led to valuable patents but have also contributed to advancements in treatments for various diseases. His role at Novartis AG has placed him at the forefront of medical discovery, fostering an environment of collaborative invention.

Collaborations

Erik has collaborated with esteemed coworkers such as Nan Ji and James J Powers, who share his passion for research and innovation. This teamwork has enabled the exploration of new ideas and methodologies within the pharmaceutical landscape, all aimed at creating effective treatment solutions.

Conclusion

In summary, Erik Meredith exemplifies the spirit of innovation with his 18 patents and ongoing contributions to the pharmaceutical field. His focus on developing unique compounds and therapeutic uses illustrates his dedication to enhancing healthcare. With a robust career at Novartis AG, Erik continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.